X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
microbiology (108) 108
beer (107) 107
biochemistry (107) 107
chemistry (107) 107
enzymology (107) 107
metallurgy (107) 107
mutation or genetic engineering (107) 107
spirits (107) 107
vinegar (107) 107
wine (107) 107
compositions or test papers therefor (105) 105
condition-responsive control in microbiological orenzymological processes (105) 105
measuring or testing processes involving enzymes, nucleicacids or microorganisms (105) 105
processes of preparing such compositions (105) 105
human necessities (51) 51
hygiene (51) 51
medical or veterinary science (51) 51
preparations for medical, dental, or toilet purposes (51) 51
investigating or analysing materials by determining theirchemical or physical properties (45) 45
measuring (45) 45
physics (45) 45
testing (45) 45
specific therapeutic activity of chemical compounds ormedicinal preparations (43) 43
compositions thereof (36) 36
culture media (36) 36
microorganisms or enzymes (36) 36
propagating, preserving or maintaining microorganisms (36) 36
humans (25) 25
organic chemistry (22) 22
index medicus (19) 19
oncology (17) 17
apparatus for enzymology or microbiology (16) 16
female (15) 15
aged (14) 14
middle aged (13) 13
nucleosides (12) 12
sugars (12) 12
derivatives thereof (11) 11
nucleic acids (11) 11
nucleotides (11) 11
peptides (10) 10
prognosis (10) 10
cancer (9) 9
male (9) 9
mutation (9) 9
survival (8) 8
adult (7) 7
aged, 80 and over (7) 7
calculating (7) 7
chemotherapy (7) 7
computing (7) 7
counting (7) 7
electric digital data processing (7) 7
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (7) 7
information and communication technology [ict] specially adaptedfor specific application fields (7) 7
lung neoplasms - genetics (7) 7
acquired-resistance (6) 6
animals (6) 6
cell line, tumor (6) 6
gene expression (6) 6
prospective studies (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
carcinoma, non-small-cell lung - genetics (5) 5
care and treatment (5) 5
cell lung-cancer (5) 5
dna-binding proteins - genetics (5) 5
drug resistance, neoplasm - genetics (5) 5
follow-up studies (5) 5
gefitinib (5) 5
gene expression profiling (5) 5
lung neoplasms - pathology (5) 5
survival analysis (5) 5
survival rate (5) 5
tumors (5) 5
analysis (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
antisense rna (4) 4
biochemistry & molecular biology (4) 4
breast-cancer (4) 4
carcinoma (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
clinical trials (4) 4
drug resistance, neoplasm (4) 4
expression (4) 4
gene expression regulation, neoplastic (4) 4
lung neoplasms - drug therapy (4) 4
open-label (4) 4
receptor, epidermal growth factor - genetics (4) 4
reverse transcriptase polymerase chain reaction (4) 4
therapy (4) 4
treatment outcome (4) 4
tyrosine kinase inhibitors (4) 4
abridged index medicus (3) 3
acrylamides - administration & dosage (3) 3
antineoplastic agents - administration & dosage (3) 3
article (3) 3
biomarkers (3) 3
cancer research (3) 3
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (174) 174
French (54) 54
German (29) 29
Portuguese (11) 11
Chinese (7) 7
Korean (4) 4
Danish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4453 - 4461
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2015, Volume 5, Issue 7, pp. 713 - 723
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug... 
Journal Article
Cell Reports, ISSN 2211-1247, 04/2018, Volume 23, Issue 3, pp. 918 - 929
Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited. We... 
ovarian cancer | biomarkers | synthetic lethality | breast cancer | DNA repair | chemotherapy | genetic interactions | BREAST-CANCER | DRUG-SENSITIVITY | POLY(ADP-RIBOSE) POLYMERASE | CELLS | HOMOLOGOUS RECOMBINATION | DNA-REPAIR | ARID1A EXPRESSION | OVARIAN-CARCINOMA | DEFICIENCY | DAMAGE | CELL BIOLOGY
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2013, Volume 3, Issue 12, pp. 1404 - 1415
Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine... 
CELL LUNG-CANCER | MET AMPLIFICATION | ONCOLOGY | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITOR | T790M MUTATION | OPEN-LABEL | AKT INHIBITOR | GEFITINIB RESISTANCE | AXL KINASE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Drug Resistance, Neoplasm | Epithelial-Mesenchymal Transition - drug effects | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | HEK293 Cells | Female | Antineoplastic Agents - pharmacology | Acrylamides - pharmacology | Mutant Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Mice, Transgenic | Mutant Proteins - metabolism | Pyrimidines - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Acrylamides - administration & dosage | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | T790M | drug resistance | NSCLC | EMT | EGFR
Journal Article